Tapentadol Phosphate Extended-Release Coating Against Ethanol Dose Dumping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical dosage forms of Tapentadol are susceptible to ethanol-induced dose dumping, leading to rapid drug release and increased plasma concentrations, posing safety risks, and do not adequately address the pharmacokinetic interactions with alcohol.
Innovation Solution
A pharmaceutical dosage form containing Tapentadol as a dihydrogenphosphate salt with phosphoric acid, coated with hydrophobic cellulose ethers like ethylcellulose and hydrophilic pore-formers, providing prolonged release and slower dissolution in aqueous ethanol compared to non-ethanolic media.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional Tapentadol dosage forms are used, then prolonged release is achieved, but they are susceptible to ethanol-induced dose dumping causing rapid drug release
Solution Approach 1:
The patent changes the chemical form of Tapentadol from conventional salts (hydrochloride, sulfate) to phosphoric acid salt, which fundamentally alters the dissolution behavior and resistance to ethanol-induced dose dumping while maintaining prolonged release properties
Solution Approach 2:
The patent uses a composite matrix formulation combining phosphoric acid salt of Tapentadol with multiple polymers (hydroxypropylmethylcellulose, ethylcellulose, polyvinyl acetate) and pore-forming agents (sorbitol, povidone) to create a robust extended-release system that resists ethanol-induced dose dumping
2Productivity
If Tapentadol is formulated for prolonged release, then dosing frequency is reduced, but pharmacokinetic interactions with alcohol increase safety risks
Solution Approach 1:
The patent changes the dissolution rate parameter by using phosphoric acid salt, which exhibits slower and more consistent dissolution in ethanolic environments compared to conventional salts, thereby reducing peak plasma concentrations when co-ingested with alcohol
Solution Approach 2:
The patent converts the potential harmful effect of ethanol (which can accelerate dissolution of conventional formulations) into a beneficial outcome by using phosphoric acid salt that exhibits reduced dissolution rate in ethanolic media, thereby preventing dose dumping and reducing pharmacokinetic interactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form offers enhanced safety by reducing the risk of dose dumping and pharmacokinetic interactions with alcohol, ensuring controlled drug release and prolonged therapeutic effect.
Implementation Method 1
coated with hydrophobic cellulose ethers like ethylcellulose
Implementation Method 2
hydrophilic pore-formers, providing prolonged release and slower dissolution
Implementation Method 3
providing prolonged release and slower dissolution in aqueous ethanol compared to non-ethanolic media
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a pharmaceutical dosage form providing prolonged release of Tapentadol, wherein Tapentadol is present in form of a salt with phosphoric acid (orthophosphoric acid), preferably as dihydrogenphosphate salt. The dosage form according to the invention provides improved prolonged release properties, is particularly resistant against ethanol induced dose dumping, and beyond such resistance provides additional safety features with regard to concomitant use of ethanol, e.g. alcoholic beverages.